Compared with tumor samples from patients at baseline or post bevacizumab monotherapy, the expression of CD8, PD-L1, and major histocompatibility complex-I (MHC-I) markedly increased after combination therapy [26]. The gene discussed is CD274; the disease is neoplasm.